Cardiff Oncology Corp (CRDF) Net earnings per share growth forecast for next year

Corporate company logo of Cardiff Oncology (CRDF)

High patent barriers and R&D costs limit entry into the targeted therapy niche. Cardiff Oncology, Inc. (CRDF) is developing onvansertib, whose compatibility with standards of care promises sustainable margins. However, the lack of commercial products leaves the company dependent on investment. The consensus estimate for net profit growth rates reflects current dynamics, where the actual value is -9.40.

Cardiff Oncology Corp (CRDF): Net earnings per share growth forecast for next year from 07/04/2022 to 11/17/2026

Summary analytical data breakdowns for Cardiff Oncology, Inc. (CRDF)

- share price and consensus valuation forecast:
Fundamental company analysis:Cardiff Oncology Inc.
Finished products of Cardiff Oncology Corp

The investment attractiveness of Cardiff Oncology, Inc. (CRDF) is based on the success of its biotechnological developments. This metric calculates the percentage change in expected earnings per share, reflecting the analysts' consensus forecast for future profitability. The one-year forward EPS growth trend allows for an assessment of the impact of geopolitical risks and regulatory barriers on the pace of drug commercialization. A stable trend in this indicator confirms the company's fundamental resilience to external shocks.

Competitor analysis for Cardiff Oncology, Inc.

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)